This study shows that rhTM, a drug currently used for the treatment of patients with systemic coagulopathy in Japan, ameliorates glucose intolerance and insulin secretion and enhances the proportion of regulatory T cells and tolerogenic dendritic cells in an experimental mouse model of diabetes, suggesting the potential expansion of its indication in clinical practice. The gene discussed is INS; the disease is Glucose intolerance.